Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 14;12(12):4042.
doi: 10.3390/jcm12124042.

Managing Early Onset Osteoporosis: The Impact of Premature Ovarian Insufficiency on Bone Health

Blazej Meczekalski  1 , Olga Niwczyk  1 , Gregory Bala  2 , Anna Szeliga  1
Affiliations
Review

Managing Early Onset Osteoporosis: The Impact of Premature Ovarian Insufficiency on Bone Health

Blazej Meczekalski et al. J Clin Med. .

Abstract

Premature ovarian insufficiency is a reproductive endocrine disorder characterized by the cessation of ovarian function before the age of 40 years. Although the etiopathology of POI remains largely unknown, certain causative factors have been identified. Individuals affected by POI are at an increased risk of experiencing bone mineral density (BMD) loss. Hormonal replacement therapy (HRT) is recommended for patients with POI to mitigate the risk of decreased BMD, starting from the time of diagnosis until reaching the average age of natural menopause. Various studies have compared the dose-effect relationship of estradiol supplementation, as well as different HRT formulations on BMD. The impact of oral contraception on reduced BMD or the potential benefits of adding testosterone to estrogen replacement therapy are still subjects of ongoing discussion. This review provides an overview of the latest advancements in the diagnosis, evaluation, and treatment of POI as it relates to BMD loss.

Keywords: BMD; POI; hormonal replacement therapy; osteoporosis; testosterone therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. Webber L., Davies M., Anderson R., Bartlett J., Braat D., Cartwright B., Cifkova R., de Muinck Keizer-Schrama S., Hogervorst E., et al. ESHRE Guideline: Management of women with premature ovarian insufficiency. [(accessed on 25 April 2023)];Hum. Reprod. 2016 31:926–937. Available online: http://www.ncbi.nlm.nih.gov/pubmed/27008889. - PubMed
    1. Kalantari H., Madani T., Zari Moradi S., Mansouri Z., Almadani N., Gourabi H., Mohseni Meybodi A. Cytogenetic analysis of 179 Iranian women with premature ovarian failure. Gynecol. Endocrinol. 2013;29:588–591. doi: 10.3109/09513590.2013.788625. - DOI - PubMed
    1. Sullivan A.K., Marcus M., Epstein M.P., Allen E.G., Anido A.E., Paquin J.J., Yadav-Shah M., Sherman S.L. Association of FMR1 repeat size with ovarian dysfunction. Hum. Reprod. 2005;20:402–412. doi: 10.1093/humrep/deh635. - DOI - PubMed
    1. Szeliga A., Calik-Ksepka A., Maciejewska-Jeske M., Grymowicz M., Smolarczyk K., Kostrzak A., Smolarczyk R., Rudnicka E., Meczekalski B. Autoimmune diseases in patients with premature ovarian insufficiency—Our current state of knowledge. Int. J. Mol. Sci. 2021;22:2594. doi: 10.3390/ijms22052594. - DOI - PMC - PubMed
    1. Gracia C.R., Sammel M.D., Freeman E., Prewitt M., Carlson C., Ray A., Vance A., Ginsberg J.P. Impact of cancer therapies on ovarian reserve. Fertil. Steril. 2012;97:134–140.e1. doi: 10.1016/j.fertnstert.2011.10.040. - DOI - PMC - PubMed

LinkOut - more resources